Annexon Biosciences

Edit info

Founded: 2011

Location: Brisbane, CA

Employee range: 50 - 200

Clinical stage: Clin3

Therapy area: Guillain-Barré syndrome

Drug types: IMM, RAR, NEU, OPH, NPH, GEN

Lead product: ANX005

Funding: $130M stock Jul 2022; $288M IPO Jul 2020; $100M Jul 2020; $75M C Dec 2018; $444M B Jun 2016; $34M A Dec 2014

annexonbio.com

linkedin.com

job board

Drug notes:

Also Clin2 Huntington's, Clin2 ALS; ANX007 Clin2 geographic atrophy; ANX009 Clin1 lupus nephritis; ANX1502 Clin1 autoimmune conditions; ANX105 Clin1 autoimmune condition/neurodegeneration

About:

Annexon Biosciences is developing novel therapeutics for neurodegenerative and autoimmune disorders. An important process involved in immune signaling is activation of the complement cascade. Annexon is focused on stopping the initiation of the classical complement pathway, which activates a powerful inflammatory response seen in autoimmune and neurodegenerative diseases. A key component of this cascade, C1q, accumulates and binds to tissues in complement-mediated diseases. To stop initiation of the cascade, Annexon is identifying therapies that target C1q, which is an early complement pathway protein, thereby preventing the cascade from activating damaging components of the immune system. Currently, Annexon is conducting ongoing clinical trials in multiple serious diseases of the body, brain and eye.